GSK (GSK)
NYSE: GSK
· Real-Time Price · USD
38.94
0.14 (0.36%)
At close: Aug 15, 2025, 12:14 PM
GSK Income Statement
Financials in GBP. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 7.99B | 7.52B | 8.12B | 8.01B | 7.88B | 7.36B | 8.05B | 8.15B | 7.18B | 6.95B | 7.38B | 7.83B | 6.93B | 9.78B | 9.53B | 9.08B | 8.09B | 7.42B |
Cost of Revenue | 2.17B | 1.94B | 2.56B | 2.4B | 2.08B | 1.94B | 2.34B | 2.27B | 1.93B | 1.94B | 2.24B | 2.42B | 2.18B | 3.69B | 3.68B | 2.89B | 2.55B | 2.48B |
Gross Profit | 5.82B | 5.58B | 5.56B | 5.62B | 5.8B | 5.43B | 5.71B | 5.88B | 5.25B | 5.01B | 5.14B | 5.41B | 4.75B | 6.09B | 5.85B | 6.19B | 5.54B | 4.94B |
Operating Income | 2.02B | 2.22B | 696M | 189M | 1.99B | 1.98B | 1.05B | 1.95B | 2.14B | 2.08B | 1.87B | 1.19B | 1.08B | 2.8B | 895M | 1.94B | 1.68B | 1.69B |
Interest Income | 50M | 54M | -51M | 32M | 24M | 32M | 35.98M | 24M | 33M | 29M | 26M | 22M | 21M | 7M | 4M | 4M | 7M | 10M |
Pretax Income | 1.89B | 2.11B | 563M | 64M | 1.5B | 1.36B | 380M | 1.79B | 1.99B | 1.91B | 1.63B | 1.01B | 896M | 2.6B | 706M | 1.75B | 1.47B | 1.52B |
Net Income | 1.44B | 1.62B | 414M | -58M | 1.17B | 1.05B | 350M | 1.46B | 1.62B | 1.49B | 1.46B | 779M | 838M | 1.8B | 749M | 1.37B | 1.4B | 1.07B |
Selling & General & Admin | 2.14B | 2.07B | 2.66B | 3.8B | 2.39B | 2.07B | 2.61B | 2.3B | 2.27B | 2.14B | 2.44B | 2.06B | 2.07B | 2.84B | 3.26B | 2.65B | 2.64B | 2.43B |
Research & Development | 2.02B | 1.46B | 2.03B | 1.46B | 1.43B | 1.37B | 2.05B | 1.57B | 1.34B | 1.26B | 1.8B | 1.35B | 1.24B | 1.17B | 1.45B | 1.49B | 1.22B | 1.12B |
Other Expenses | -366M | -169M | 168M | 167M | n/a | n/a | n/a | n/a | n/a | -477M | -965M | 813M | 364M | -722M | -238M | 114M | -1M | -300M |
Operating Expenses | 3.8B | 3.36B | 4.86B | 5.43B | 3.82B | 3.44B | 4.66B | 3.93B | 3.1B | 2.93B | 3.27B | 4.21B | 3.67B | 3.29B | 4.95B | 4.25B | 3.86B | 3.25B |
Interest Expense | 184M | 162M | 144M | 156M | 174M | 166M | 275.41M | 182M | 185M | 203M | 270M | 200M | 204M | 205M | 191M | 195M | 192M | 201M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | -75M | -17M | -65M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 5.96B | 5.3B | 7.42B | 7.82B | 5.9B | 5.38B | 7B | 6.2B | 5.04B | 4.87B | 5.51B | 6.64B | 5.85B | 6.98B | 8.63B | 7.14B | 6.42B | 5.72B |
Income Tax Expense | 241M | 336M | 62M | -1M | 191M | 274M | -19M | 257M | 242M | 276M | 1M | 233M | 150M | 431M | -224M | 380M | -68M | 258M |
Shares Outstanding (Basic) | 2.03B | 2.04B | 2.04B | 2.04B | 2.04B | 2.03B | 2.03B | 2.03B | 2.03B | 2.02B | 2.02B | 2.02B | 2.01B | 2.01B | 2B | 2B | 2B | 2B |
Shares Outstanding (Diluted) | 2.06B | 2.07B | 2.07B | 2.07B | 2.06B | 2.06B | 2.06B | 2.06B | 2.05B | 2.04B | 2.05B | 2.04B | 2.03B | 2.03B | 2.04B | 2.03B | 2.02B | 2.01B |
EPS (Basic) | 0.72 | 0.80 | 0.20 | -0.03 | 0.58 | 0.52 | 0.17 | 0.72 | 0.80 | 0.74 | 0.74 | 0.38 | 0.42 | 0.90 | 0.38 | 0.58 | 0.70 | 0.54 |
EPS (Diluted) | 0.70 | 0.78 | 0.20 | -0.03 | 0.56 | 0.50 | 0.17 | 0.72 | 0.80 | 0.72 | 0.74 | 0.38 | 0.42 | 0.88 | 0.36 | 0.58 | 0.70 | 0.54 |
EBITDA | 3.23B | 3.09B | 1.12B | 1.17B | 2.85B | 2.8B | 2.23B | 2.55B | 2.45B | 2.56B | 1.9B | 3.5B | 1.73B | 3.52B | 1.41B | 2.93B | 2.31B | 1.52B |
EBIT | 2.07B | 2.27B | 707M | 220M | 1.67B | 1.52B | 602M | 1.97B | 2.17B | 2.11B | 1.84B | 1.21B | 1.1B | 2.81B | 899M | 1.95B | 1.65B | 1.72B |
Depreciation & Amortization | 1.16B | 823M | 412M | 951M | 639M | 549M | 1.18B | 579M | 452M | 640M | 7M | 956M | 631M | 704M | 513M | 986M | 664M | 361M |